1. Home
  2. PLRX vs ZTEK Comparison

PLRX vs ZTEK Comparison

Compare PLRX & ZTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pliant Therapeutics Inc.

PLRX

Pliant Therapeutics Inc.

HOLD

Current Price

$1.14

Market Cap

71.5M

Sector

Health Care

ML Signal

HOLD

Logo Zentek Ltd.

ZTEK

Zentek Ltd.

HOLD

Current Price

$0.59

Market Cap

59.5M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLRX
ZTEK
Founded
2015
2008
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
71.5M
59.5M
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
PLRX
ZTEK
Price
$1.14
$0.59
Analyst Decision
Hold
Analyst Count
4
0
Target Price
$2.67
N/A
AVG Volume (30 Days)
367.4K
114.2K
Earning Date
05-06-2026
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
29.97
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.02
$0.37
52 Week High
$1.95
$1.24

Technical Indicators

Market Signals
Indicator
PLRX
ZTEK
Relative Strength Index (RSI) 57.02 52.05
Support Level $1.12 $0.55
Resistance Level $1.26 $0.74
Average True Range (ATR) 0.04 0.05
MACD 0.01 -0.01
Stochastic Oscillator 57.14 23.39

Price Performance

Historical Comparison
PLRX
ZTEK

About PLRX Pliant Therapeutics Inc.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

About ZTEK Zentek Ltd.

Zentek Ltd is engaged in developing opportunities in the graphene and related nano-materials industry based on its intellectual property, patents, and Albany graphite. The Company's operating segments are Intellectual Property Development, Biotech, and Albany Project. Intellectual Property Development includes the manufacturing and distribution of graphene-related products. Biotech includes service revenue generated through aptamer technology. The Albany Project includes the exploration and evaluation of assets and mineral exploration activities.

Share on Social Networks: